0.84
Cognition Therapeutics Inc Borsa (CGTX) Ultime notizie
What drives Cognition Therapeutics Inc. stock priceExceptional profit velocity - PrintWeekIndia
Cognition Therapeutics Inc. Stock Analysis and ForecastStrong return on investment - Autocar Professional
What analysts say about Cognition Therapeutics Inc. stockFree Bull & Bear Market Updates - Autocar Professional
Is Cognition Therapeutics Inc. a good long term investmentFree Predictions - jammulinksnews.com
Cognition Therapeutics Publishes Proteomic Analysis - GlobeNewswire
Cognition Therapeutics reports positive results for Alzheimer’s drug - Investing.com
Cognition Therapeutics Publishes Phase 2 Study Results of Zervimesine for Alzheimer's Disease in Alzheimer's & Dementia Journal - Nasdaq
Cognition Therapeutics Publishes Proteomic Analysis Elucidating Zervimesine’s Protection of Neurons and Synapses in Alzheimer’s Disease - The Manila Times
Breakthrough: New Alzheimer's Drug Protects Brain Cells from Death, Phase 2 Study Reveals - Stock Titan
How high can Cognition Therapeutics Inc. stock price go in 2025Capital Efficient Investment Tips - beatles.ru
Dementia Associated with Alzheimer’s Disease Drug - GlobeNewswire
Lewy Body Dementia Market Set to Grow Substantially Through - openPR.com
Cognition Therapeutics stock soars after DLB study results - Investing.com
Cognition Therapeutics stock soars after DLB study results By Investing.com - Investing.com Nigeria
CGTX Soars 19.72% on Promising Dementia Drug Results - AInvest
Cognition Therapeutics, Inc. Reports Promising Results for Zervimesine in Phase 2 Alzheimer’s and Dementia with Lewy Bodies Studies - Nasdaq
Cognition Therapeutics' Positive Clinical Data from - GlobeNewswire
Breakthrough DLB Treatment: Clinical Trial Reveals 86% Symptom Improvement in Dementia Patients - Stock Titan
Cognition Enhancing Drugs Market CAGR 5.6 % innovations and key - openPR.com
How Cognition Therapeutics Inc. stock performs during market volatilityMomentum Buy Alert - Newser
Why Cognition Therapeutics Inc. stock attracts strong analyst attentionControlled Risk High Reward Plan - Newser
What makes Cognition Therapeutics Inc. stock price move sharplyFree High-Profit Stock Picks - Newser
Cognition Therapeutics shares fall 1.16% premarket after Karolinska Development's portfolio company Umecrine Cognition raises SEK 24.6 million for clinical development. - AInvest
CGTX’s 2025 Market Saga: Unraveling the Story of Gains and Losses - investchronicle.com
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Receives Average Rating of “Buy” from Analysts - Defense World
Cognition Therapeutics (NASDAQ:CGTX) Rating Lowered to Strong Sell at Wall Street Zen - Defense World
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):